VentriPoint Diagnostics Ltd VPTDF

Primary Symbol: V.VPT

Healthcare Medical Devices

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > VPT Financials: A story that just lacks traction

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Apr 30, 2024 5:06pm

49 Views

Post# 36015920

RE:VPT Financials: A story that just lacks traction

GrahamB wrote: Revenue $ 49,183 $ on total operating expenses 4,972,932
Net loss for the year $ (4,871,937)

For context:
Total revenue for year ending Dec. 31, 2022 = 68,167

Total revenue for year ending Dec. 31, 2021 = ZERO

Total revenue for year ending Dec. 31, 2020 = $36,017

Total revenue for year ending Dec. 31, 2019 = $81,023

Total revenue for year ending Dec. 31, 2018 = $60,177

ALL DATA FROM SEDAR.COM

And the predictions on the number of sales?

The initial target were revised from 75-100 units in FY2022 to 40-45 units.

From ceo-many (including the resident pumper/?basher here) seem to be mesmerized by cardinal who said:
“@cardinal They will have roughly 45 sales by year end. Q1 and 2 will be very very large. They will be way past the number that draws attention from buyers.’

Here is the guidance from the company :

1. Nine distributors appointed in USA to cover the entire country to join UK and European distributors for a total of 11 distributors,
3. Sales team now has 33 sales and marketing representatives across the USA, Europe and UK,

With the assistance of our distributors and our internal sales force, the Company now has a list of over 4,000 cardiologists who have a practice where the VMS+ would improve their ability to assess and monitor their patients In addition, our sales team (direct and distributor) already have a relationship with all these potential customers in US, UK and Europe. Hence, the Company now has a full funnel of leads. Our sales team has been actively scheduling appointments to make them aware of the clinical benefits of the VMS+.

https://www.thenewswire.com/press-releases/1Av7FPeNe-ventripoint-diagnostics-provides-a-corporate-update-and-announces-new-investor-relations-initiative.html

We Heard chatter here of” 100% conversion” rate
Were the 4000 leads just business cards in a fishbowl ata conference?

IMO More hype than beef-The saviour Dr GA, replaced by the new leader Alvira, who was proclaimed to be the sales and organizational person needed , replaced by…..
The story continues, but the numbers tell a story.

Where is the demand for this product-why wont it sell?

What happened to Edison and GE(the edison site doesnt list VPT icon or any - anymore when I last checked-anyone able to show a new link???)
What happenned to the elephant going for a walk?
, China, Ascend, the other multiple partnerships

Based on the cash burn and the cash remaining a cash raise is needed now urgently IMO

BUT its all imo

Don’t invest or not based on what I say
For entertainment only